Combined General Meeting of May 21, 2025

Core Points - The Combined General Shareholders' Meeting of EUROAPI was held on May 21, 2025, in Paris, where all resolutions proposed by the Board of Directors were approved by shareholders [1][2] - The meeting included the approval of the unconsolidated and consolidated financial statements for the year 2024, compensation arrangements for corporate officers, and financial authorizations [2] - EUROAPI's Board of Directors now consists of ten members, with a majority being independent directors, including five independent members and two employee representatives [2] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, being a leading player in active pharmaceutical ingredients with around 200 products in its portfolio [3][4] - The company operates six manufacturing sites in Europe and employs approximately 3,430 people, ensuring high-quality API manufacturing for customers in over 80 countries [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI and has strong research and development capabilities [4]